Publication: Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients
dc.contributor.author | Kawin Leelawat | en_US |
dc.contributor.author | Surang Leelawat | en_US |
dc.contributor.author | Thawee Ratanachu-Ek | en_US |
dc.contributor.author | Somboon Trubwongchareon | en_US |
dc.contributor.author | Jerasak Wannaprasert | en_US |
dc.contributor.author | Saad Tripongkaruna | en_US |
dc.contributor.author | Suchart Chantawibul | en_US |
dc.contributor.author | Panadda Tepaksorn | en_US |
dc.contributor.other | Rajavithi Hospital | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Rangsit University | en_US |
dc.contributor.other | National Institutes of Health, Bethesda | en_US |
dc.date.accessioned | 2018-08-20T07:14:50Z | |
dc.date.available | 2018-08-20T07:14:50Z | |
dc.date.issued | 2006-07-14 | en_US |
dc.description.abstract | Aim: To investigate human telomerase reverse transcriptase (hTERT) mRNA in the serum of cholangiocarcinoma patients. Methods: The serum of thirty three cholangiocarcinoma patients, forty one benign biliary tract disease patients and ten healthy volunteers were collected and analyzed for the expression of hTERT mRNA by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). We then examined the correlation between values of serum hTERT mRNA and the pathological staging of cholangiocarcinoma. Results: hTERT mRNA was detected in 28 of 33 (84.85%) of serum obtained from cholangiocarcinoma patients and 9 of 41 (21.9%) of serum obtained from benign biliary tract disease patients. hTERT mRNA was not detected in any serum obtained from healthy volunteers. on the other hand the common tumor marker, CA19-9 was detected in 20 of 33 (60.6%) of serum obtained from cholangiocarcinoma patients and 8 of 41 (19.5%) of serum obtained from benign biliary tract disease patients. However, no correlation was found between the present of serum hTERT mRNA and tumor staging. Conclusion: These results indicate that the detection of circulating hTERT mRNA was identified in almost all cholangiocarcinoma patients. It offers a novel tumor marker, which can be used as a complementary study for diagnosis of cholangiocarcinoma. © 2006 The WJG Press. All rights reserved. | en_US |
dc.identifier.citation | World Journal of Gastroenterology. Vol.12, No.26 (2006), 4195-4198 | en_US |
dc.identifier.doi | 10.3748/wjg.v12.i26.4195 | en_US |
dc.identifier.issn | 10079327 | en_US |
dc.identifier.other | 2-s2.0-33748605027 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/23696 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33748605027&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.title | Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33748605027&origin=inward | en_US |